Clinical results of the use of mitotane for adrenocortical carcinoma

Clinical results of the use of mitotane for adrenocortical carcinoma

Mitotane (o,p'-DDD) acts mainly as an inhibitor of intramitochondrial pregnenolone and cortisol synthesis. Its adrenolytic effect depends on metabolic activation due to conversion to o,p'-DDA and o,p'-DDE. The drug has been used for 40 years in the treatment of adrenocortical carcinom...

Full description

Bibliographic Details
Main Author:	A.A. Kasperlik-Zaluska
Format:	Article
Language:	English
Published:	Associação Brasileira de Divulgação Científica 2000-10-01
Series:	Brazilian Journal of Medical and Biological Research
Subjects:	mitotane adrenocortical carcinoma Cushing's syndrome
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2000001000008

Similar Items

Characterization of hyperlipidemia secondary to mitotane in adrenocortical carcinoma
by: Nadia Gagnon, et al.
Published: (2023-01-01)

Adrenocortical cancer: late diagnosis of the disease on the example of a clinical case. Case report
by: Evgenia A. Starostina, et al.
Published: (2023-12-01)

Adrenocortical Carcinoma With Cushing’s Syndrome and Hyperandrogenism in a 28-Year-Old Pregnant Female
by: Michael John Marino, DO, et al.
Published: (2023-05-01)

Recovery of Adrenal Insufficiency Is Frequent After Adjuvant Mitotane Therapy in Patients with Adrenocortical Carcinoma
by: Jonathan Poirier, et al.
Published: (2020-03-01)

Molecular Mechanisms of Mitotane Action in Adrenocortical Cancer Based on In Vitro Studies
by: Marco Lo Iacono, et al.
Published: (2021-10-01)

Involvement of 27-Hydroxycholesterol in Mitotane Action on Adrenocortical Carcinoma
by: Antonina Germano, et al.
Published: (2020-04-01)

Low-dose mitotane-induced neurological and endocrinological complication in a 5-year-old girl with adrenocortical carcinoma
by: You Joung Heo, et al.
Published: (2022-09-01)

Neurological adverse events of mitotane in adrenocortical carcinoma: results of a pilot study
by: Marilda Mormando, et al.
Published: (2023-08-01)

Population Pharmacokinetics Modelling and Simulation of Mitotane in Patients with Adrenocortical Carcinoma: An Individualized Dose Regimen to Target All Patients at Three Months?
by: Yoann Cazaubon, et al.
Published: (2019-10-01)

The experience with the application of first-line chemotherapy regimen with EDP-M (etoposide + doxorubicin + cisplatin + mitotane) in patients with advanced adrenocortical carcinoma in the Russian Federation
by: A A Kolomeytseva, et al.
Published: (2017-09-01)

Adrenocortical carcinoma: Diagnosis, prognostic classification and treatment of localized and advanced disease
by: Rossella Libé, et al.
Published: (2023-01-01)

Isosexual precocious pseudopuberty during mitotane treatment in a child with adrenocortical carcinoma: A case report
by: Maria Riedmeier, et al.
Published: (2024-06-01)

Hypogonadism and sexual function in men affected by adrenocortical carcinoma under mitotane therapy
by: Letizia Canu, et al.
Published: (2024-01-01)

The tyrosine kinase inhibitor nilotinib is more efficient than mitotane in decreasing cell viability in spheroids prepared from adrenocortical carcinoma cells
by: Elaine Silveira, et al.
Published: (2018-03-01)

The impact of mitotane therapy on serum-free proteins in patients with adrenocortical carcinoma
by: Magdalena Lech, et al.
Published: (2024-02-01)

What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question
by: Vittoria Basile, et al.
Published: (2021-04-01)

Albumin/Mitotane Interaction Affects Drug Activity in Adrenocortical Carcinoma Cells: Smoke and Mirrors on Mitotane Effect with Possible Implications for Patients’ Management
by: Aurora Schiavon, et al.
Published: (2023-11-01)

Effect of Mitotane on Male Gonadal Function
by: Federica Innocenti, et al.
Published: (2023-06-01)

Adrenocortical carcinoma: A tumor with poor answer to classic chemotherapy
by: Sava Alexandra Daniela, et al.
Published: (2023-12-01)

Adrenocortical carcinoma: Report of two cases
by: C Aparna, et al.
Published: (2011-01-01)

A case of adrenocortical carcinoma accompanying secondary acute adrenal hypofunction postoperation
by: Kai Kou, et al.
Published: (2018-03-01)

Adrenocortical carcinoma in pregnancy: A diagnostic dilemma
by: Ankush Jairath, et al.
Published: (2014-01-01)

Case Report: Adrenocortical carcinoma in children—symptoms, diagnosis, and treatment
by: Estera Zagojska, et al.
Published: (2023-11-01)

Long-term partial response in a patient with liver metastasis of primary adrenocortical carcinoma with adjuvant mitotane plus transcatheter arterial chemoembolization and microwave ablation: a case report
by: Jianhua Deng, et al.
Published: (2023-05-01)

Local advanced adrenocortical cancer with a long‐term recurrence‐free survival treated with complete surgical excision and adjuvant therapy with a very low‐dose mitotane
by: Yuumi Tokura, et al.
Published: (2020-11-01)

Mitotane Nanocarriers for the Treatment of Adrenocortical Carcinoma: Evaluation of Albumin-Stabilized Nanoparticles and Liposomes in a Preclinical In Vitro Study with 3D Spheroids
by: Carolin Langer, et al.
Published: (2022-09-01)

Complete Remission of Advanced Adrenocortical Cancer Following Mitotane Monotherapy: A Case Report and Literature Review of Predictive Markers
by: Judit Tőke, et al.
Published: (2021-05-01)

EDP-mitotane in children: reassuring evidence of reversible side-effects and neurotoxicity
by: Rebecca V. Steenaard, et al.
Published: (2022-04-01)

Adrenocortical neoplasms in children: Treatment and outcomes
by: Vishesh Jain, et al.
Published: (2022-01-01)

Medical Approaches in Adrenocortical Carcinoma
by: Rosa Maria Paragliola, et al.
Published: (2020-11-01)

Adjuvant Therapy in Adrenocortical Carcinoma: Reflections and Future Directions
by: Sara Bedrose, et al.
Published: (2020-02-01)

Estrogen-Like Effect of Mitotane Explained by Its Agonist Activity on Estrogen Receptor-α
by: Elisa Rossini, et al.
Published: (2021-06-01)

Massive adrenocortical carcinoma presenting as peripheral edema: a case report
by: David A. Goodkin
Published: (2022-06-01)

Adjuvant therapy in adrenocortical carcinoma: prognostic factors and treatment options
by: Ruaa Al-Ward, et al.
Published: (2023-01-01)

Health-Related Quality of Life in Adrenocortical Carcinoma
by: Rebecca V. Steenaard, et al.
Published: (2019-10-01)

Metabolic and Endocrine Toxicities of Mitotane: A Systematic Review
by: Marta Bianchini, et al.
Published: (2021-10-01)

Prognostic factors and mitotane treatment of adrenocortical cancer. Two decades of experience from an institutional case series
by: Judit Tőke, et al.
Published: (2022-09-01)

Adrenocortical carcinoma (ACC): diagnosis, prognosis and treatment.
by: Rossella eLibé
Published: (2015-07-01)

Childhood adrenocortical carcinoma: Case report and review
by: Abhay Gundgurthi, et al.
Published: (2012-01-01)

Efficacy of the EDP-M Scheme Plus Adjunctive Surgery in the Management of Patients with Advanced Adrenocortical Carcinoma: The Brescia Experience
by: Marta Laganà, et al.
Published: (2020-04-01)